Quick Facts

• Main Use: Assists in the digestion of lactose (milk sugar).
• Therapeutic Benefit: Helps prevent the gastrointestinal symptoms associated with lactose intolerance.
• Key Action: Replaces the natural enzyme required to break down milk sugar.

---

Therapeutic Overview

Lactas is an over-the-counter digestive aid used to help manage the condition of lactose intolerance. Its main therapeutic function is to assist the body in the digestion of lactose, the sugar naturally present in milk and other dairy products. Individuals with lactose intolerance have reduced production of the natural enzyme (lactase) needed to break down this sugar in the small intestine.

When taken with lactose-containing food, Lactas supplements may reduce or prevent the common gastrointestinal symptoms of this condition. These uncomfortable symptoms can include abdominal pain, gas, and diarrhea that follow the consumption of dairy. By enabling the breakdown of lactose into easily absorbed sugars, the use of this product allows individuals to consume dairy products without experiencing these adverse reactions. Treating lactose intolerance in this manner helps people incorporate dairy into their nutritional regimen, which is a valuable source of nutrients like calcium and vitamin D.

The official regulatory profile for Lactas (Tilactase) defines strict eligibility and non-eligibility criteria. Use is absolutely contraindicated in patients with known Hypersensitivity (severe allergy) to Tilactase or any of its excipients. It is also prohibited for individuals diagnosed with Galactosemia, as the enzyme's action produces galactose.

Use is established and permitted for adults and older adults with lactose intolerance. However, specific age-related restrictions apply: use of solid oral forms (tablets/capsules) is generally not recommended or not established for children under 4 years of age.

For pregnant and lactating patients, the product is often classified for conditional use, recommended only if clearly needed due to limited controlled data in human subjects. No specific restrictions are documented for patients with hepatic impairment or renal impairment, as the enzyme is not absorbed systemically. Patients with Phenylketonuria (PKU) may need to avoid certain formulations if they contain aspartame.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile for Tilactase is characterized by the absence of documented systemic drug-drug interactions with other active pharmaceutical ingredients. This finding is consistent across official regulatory guidance from major government health authorities.

Tilactase is an enzyme replacement designed to function locally within the gastrointestinal tract and is not absorbed into the systemic circulation. Consequently, its official profile states that it does not participate in systemic pharmacokinetic interaction mechanisms. This classification means no formal contraindications, metabolic interactions, or exposure-modifying effects are documented between the active enzyme and co-administered medicines, nor are there mandatory timing separation requirements.

Excipient-Based Interaction Restriction

While the active ingredient lacks systemic interaction risks, official regulatory guidance documents a crucial restriction related to excipients in certain product formulations. This is classified as a population-specific interaction note.

Interaction Type	Requirement/Restriction
Drug-Drug Interactions	No clinically significant interactions are documented with other active medicines.
Metabolic Interactions	No documented CYP-mediated or transporter interactions.
Specific Population Restriction	Formulations containing aspartame must be avoided by patients diagnosed with Phenylketonuria (PKU).

This restriction requires individuals with Phenylketonuria to ensure the specific preparation of Lactas they use is aspartame-free.

Molecular Target and Interaction

Lactas functions as an inhibitor, primarily targeting the Janus Kinase 1 (JAK1) enzyme. It achieves this by binding directly to the ATP-binding site within the catalytic domain of JAK1 . This interaction prevents the enzyme from initiating its phosphorylation activity.

---

Intracellular Signaling Cascade

This specific JAK1 inhibition reduces the subsequent phosphorylation of STAT proteins (Signal Transducer and Activator of Transcription). The resulting modulation of signaling cascades leads to the altered transcription of various pro-inflammatory cytokines, including Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha). Lactas exhibits high selectivity for JAK1 over other Janus Kinase family members (JAK2, JAK3, and TYK2).

---

Downstream Physiological Modulation

The systemic modulation of cytokine activity is mechanistically linked to a reduction in the differentiation and activity of osteoclasts (bone-resorbing cells) and the subsequent changes in cell population dynamics within the immune and skeletal systems.

Lactas (Tilactase) is formulated for oral administration as an enzyme replacement, available in various solid dosage forms like tablets and capsules, as well as liquid preparations. The usage pattern is strictly intermittent and event-driven, intended to be taken only with or immediately prior to the consumption of a food or beverage containing lactose. The enzyme acts locally within the gastrointestinal tract and is not absorbed into systemic circulation.

---

Dosing and Frequency

The dose is quantified using FCC Lactase Units (ALU). The standard dosage for adults and children 4 years is typically within the 3,000 to 9,000 unit range per single administration. There are established limits for use: a single dose must not exceed 18,000 FCC ALU, and the total intake over a 24-hour period must not exceed 54,000 FCC ALU. This dose must be repeated every time a lactose-containing food is consumed.

---

Administration Conditions

The proper use of Lactas requires attention to timing and, for liquid forms, temperature. Administration is time-sensitive, directly coinciding with the meal. For liquid preparations, the enzyme is sensitive to heat and should only be mixed into cold or warm liquids; hot or boiling carriers must be avoided as they will destroy the enzyme's activity. For infants, the liquid preparation follows a distinct protocol, often involving pre-digestion of breast milk or formula by mixing the drops into the liquid and allowing a specific time period before feeding.

Dapagliflozin: Recent Clinical Evidence

Dapagliflozin belongs to the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class and was initially studied in relation to managing type 2 diabetes mellitus, where research focuses on its effect of increasing urinary glucose excretion.

Mechanism of Action (Class Reference)

Dapagliflozin belongs to a drug class whose action involves selective inhibition of SGLT2 in the kidneys. This class of drugs has been observed to increase the amount of glucose excreted through the urine.

---

Cardiovascular and Renal Outcomes

Beyond research regarding blood glucose in patients with type 2 diabetes, clinical trials have observed associations between its use and certain cardiovascular and renal outcomes. Specifically, studies reported a lower incidence of hospitalization for heart failure.

In investigations involving patients with heart failure, regardless of the presence of diabetes, outcomes indicated an observed reduction in the composite endpoint of cardiovascular death and first worsening heart failure event. The observed effects occurred across diverse patient groups, suggesting the findings may be independent of baseline glycemic control.

Specific evidence relating to chronic kidney disease (CKD) included observations of a lower incidence of a composite endpoint, which incorporated sustained decline in kidney function, need for renal replacement therapy, and mortality associated with kidney or cardiovascular causes. This finding related to kidney outcomes was observed regardless of the patient’s diabetic status.

Ongoing Research

Current research continues to explore the full range of dapagliflozin’s pharmacological actions and its long-term findings across various patient populations with cardiometabolic diseases.

Key Studies & References

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF Trial)

Common questions about Lactas (FAQ)

Q: What is Lactas, and how does it work to treat lactose intolerance?

A: Lactas is a dietary supplement containing the enzyme lactase (beta-galactosidase). This enzyme is naturally produced in the small intestine but is deficient in people with lactose intolerance. When taken before consuming dairy products, Lactas works by helping to break down lactose, the sugar found in milk and other dairy items, into simpler sugars (glucose and galactose) that the body can easily absorb. This process prevents undigested lactose from reaching the large intestine, where it would otherwise cause uncomfortable gastrointestinal symptoms.

Q: How should I take Lactas for the best results?

A: Lactas should be taken with the first bite or sip of any food or drink that contains lactose. The lactase enzyme acts locally in your digestive system to break down the lactose in the meal you are consuming. If you wait until after you've finished the food, the enzyme may not be as effective because the lactose will have already passed into the lower digestive tract. You should follow the dosage instructions provided on the product packaging, as the number of capsules or chewable tablets needed can vary based on the specific product's strength and the amount of lactose in your meal.

Q: Are there any common side effects associated with taking Lactas?

A: When taken as directed, Lactas is generally well-tolerated and not associated with significant side effects. Because Lactas helps improve the digestion of lactose, it usually reduces the symptoms of lactose intolerance (such as gas, bloating, and diarrhea) rather than causing them. In rare instances, some individuals may experience mild, temporary gastrointestinal discomfort, such as an upset stomach, but this is uncommon. If you notice any unexpected or severe reactions, you should stop taking the product and consult a healthcare provider.

Q: Can Lactas be taken by children?

A: Lactas is often appropriate for children who have been diagnosed with lactose intolerance, but only under the guidance of a pediatrician or qualified healthcare provider. It is important to confirm that the child’s symptoms are indeed due to lactose intolerance before starting any supplement. The dosage for children may need to be adjusted based on their age, weight, and the amount of lactose they consume. Always use a product formulated for or appropriate for children and strictly follow the directions provided by a healthcare professional.

Q: Does Lactas cure lactose intolerance, or is it a long-term treatment?

A: Lactas is a management tool, not a cure, for lactose intolerance. Lactose intolerance is typically a lifelong condition caused by the body's decreased ability to produce its own lactase enzyme. Taking the Lactas supplement only provides the necessary enzyme for the current meal being consumed. It does not restore the body's natural ability to produce lactase. Therefore, individuals with lactose intolerance must continue to take Lactas whenever they consume lactose-containing products to prevent digestive symptoms.

How to Store and Dispose of Lactase Enzyme Products

The storage and disposal of lactase enzyme products (Tilactase) must adhere strictly to official regulatory guidelines to maintain product stability and ensure public safety.

Official Storage Requirements

• Temperature and Protection: The product must be stored at room temperature, typically between 20 C and 25 C. Storage locations must be dry and protected from excessive heat and moisture.
• Handling Constraints: The medication must not be frozen and should not be refrigerated if it is a solid oral form (capsule/tablet).
• Container Integrity: Keep the product in its original container and ensure the container is tightly closed.
• Child Safety: The medication must be kept out of the reach and sight of children and pets.

Official Disposal Rules

Expired or unused lactase should be properly discarded. The official instruction is not to flush the product down the toilet or pour it into a drain. Instead, utilize a drug take-back program or follow the approved process of mixing the medication with an undesirable substance and placing it in a sealed bag before throwing it into the household trash.